RESUMEN
AIM: To investigate the proportion of children with moderate to profound hearing loss who have congenital cytomegalovirus (cCMV) infection. METHOD: Retrospective analysis of CMV dried blood spot (DBS) polymerase chain reaction (PCR) in children with moderate to profound hearing impairment referred to tertiary referral centres in Queensland. Participants were under 18 years old with no readily identified cause of hearing impairment, between 2008 and 2011. The primary outcome measure was DBS CMV PCR. Other outcome measures for cases referred to the Childhood Hearing Clinic (CHC) at the Mater Children's Hospital were level of hearing impairment and the neonatal hearing screen result. RESULTS: Of DBS CMV PCR testing for 106 children at the CHC for 2008 to 2011 inclusive, nine (8.5%) were positive (five with bilateral hearing impairment, four with unilateral hearing impairment). The prevalence of cCMV infection in children with moderate to profound hearing impairment was 8.4%, consistent with the statewide rate of 9.4% for 2008 to mid-2011. CONCLUSION: cCMV is a significant cause of hearing impairment in Queensland children. Investigation for cCMV by retrospective DBS CMV PCR should be part of the routine investigation of all babies and young children with hearing impairment. However early diagnosis is preferable and could be achieved by routine early screening of all newborns with hearing impairment for CMV before 3 weeks of age. The healthy hearing screening programme is a routine part of neonatal care. Enhancing the integration of screening for cCMV may reduce the current delays in diagnosis and should be evaluated.
RESUMEN
BACKGROUND: Live attenuated varicella vaccine is considered a safe vaccine with serious adverse effects reported only in immunocompromised children. We describe a severe life-threatening infection with varicella vaccine virus causing rash and pneumonitis in a 6-year-old boy with no apparent immunodeficiency. METHODS AND RESULTS: Polymerase chain reaction (PCR) analysis of vesicle swab samples demonstrated varicella zoster virus (VZV). Sequencing of the PCR product demonstrated 100% homology with human herpesvirus 3 strain VZV-Oka ORF62 gene. Routine immunologic investigations failed to demonstrate any abnormality. Total leukocyte, lymphocyte, and neutrophil counts and lymphocyte subsets were normal. Immunoglobulins, C3, C4, and CH50 were intact. Specific IgG to protein and polysaccharide antigens and to Epstein-Barr virus and cytomegalovirus were present. Normal lymphocyte proliferation to phytohemagglutinin and VZV antigens was detected. Neutrophil function and natural killer (NK) cell activity were normal. The analysis of invariant NK T (iNKT) cell numbers and function revealed diminished iNKT cells, reported once previously and unique to our patient, deficient expression of the cognate receptor, CD1d. CONCLUSIONS: This report provides a further link between deficiency of the iNKT/CD1d pathway and increased susceptibility to varicella vaccine virus, suggesting an important role of this innate pathway in host defense against yet another member of the herpesvirus family.
Asunto(s)
Antígenos CD1d/metabolismo , Vacuna contra la Varicela/efectos adversos , Varicela/inmunología , Herpesvirus Humano 3/inmunología , Células T Asesinas Naturales/inmunología , Vacunación/efectos adversos , Proliferación Celular , Varicela/tratamiento farmacológico , Varicela/virología , Niño , Humanos , Interferón gamma/metabolismo , Recuento de Linfocitos , Masculino , Células T Asesinas Naturales/metabolismo , Vacunas Atenuadas/efectos adversosRESUMEN
This communication reports invasive amoebic colitis and late onset amoebic liver abscess in three members of a group of 12 Australian travellers to Timor-Leste (TL). This is the first report of Entamoeba histolytica infection from TL. Clinicians in Australia need to consider amoebiasis in the differential diagnosis in travellers returning with colitis, abdominal pain and fever. Presentation with amoebic liver abscess months after exposure is rare but should be suspected in symptomatic individuals with a relevant history of travel.